<p>由于主要的美国股指最近收盘上涨，从因担忧政府可能停摆而导致的亏损周中反弹，科技股占主导的纳斯达克表现出韧性，涨幅为 0.5%。在市场波动和经济不确定性的背景下，识别高增长科技股需要评估那些展现出强大创新能力和适应快速变化市场条件的公司。</p>
<h3>美国十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACADIA 制药</td>
<td>10.33%</td>
<td>23.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>ADMA 生物技术</td>
<td>20.60%</td>
<td>23.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir 技术</td>
<td>25.11%</td>
<td>31.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>65.52%</td>
<td>68.63%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.20%</td>
<td>32.07%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>OS 疗法</td>
<td>56.64%</td>
<td>68.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle 互联网集团</td>
<td>28.59%</td>
<td>82.71%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Aldeyra 治疗学</td>
<td>42.88%</td>
<td>74.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Vanda 制药</td>
<td>22.66%</td>
<td>59.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Gorilla 科技集团</td>
<td>32.75%</td>
<td>122.61%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国高增长科技和人工智能股票筛选器中的 67 只股票的完整列表。</p>
<p>在这里，我们重点介绍我们独家的筛选器中的几只最爱。</p>
<h2>MiMedx 集团 (MDXG)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> MiMedx 集团公司开发和分销胎盘组织移植物，服务于多个医疗保健领域，市值约为 10.3 亿美元。</p>
<p><strong>运营：</strong> 该公司主要通过其生物技术部门产生收入，特别是针对初创企业，报告的收入为 3.6377 亿美元。</p>
<p>MiMedx 集团是一家专注于先进伤口护理的生物技术公司，正在应对一个充满挑战但充满机会的市场环境。最近，该公司将全年收入预期上调至低双位数，尽管与去年相比，净收入从 1763 万美元下降至 962 万美元。与 Vaporox 的战略联盟暗示了在伤口护理产品的共同推广和市场营销方面的积极举措，可能增强其市场覆盖率和产品有效性。这一合作以及对 Vaporox 的投资可能通过将创新疗法如 VHT 整合到其产品中，提升 MiMedx 的市场地位，这些疗法在临床研究和实际应用中显示出良好的效果。尽管过去一年盈利波动显著下降（-59.3%），但预测显示未来三年年均盈利增长 24.6%，超过行业和市场平均水平。</p>
<ul>
<li>点击探索我们在 MiMedx 集团健康报告中的详细发现。</li>
<li>了解 MiMedx 集团的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da86cace-6e02-47ab-b8cb-096c3db7abd9/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da86cace-6e02-47ab-b8cb-096c3db7abd9/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 9 月 MDXG 收入和支出明细</p>
<h2>National CineMedia (NCMI)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> National CineMedia, Inc.通过其子公司 National CineMedia, LLC 在北美运营一个影院广告网络，市值为 4.3481 亿美元。</p>
<p><strong>运营：</strong> 该公司主要通过广告产生收入，总计 2.353 亿美元。</p>
<p>在一个充满挑战的环境中，National CineMedia (NCMI) 正在经历显著的财务动荡，其 2025 年第二季度的结果显示，销售额同比从 5470 万美元下降至 5180 万美元，净亏损从去年同期的 870 万美元加深至 1070 万美元。尽管面临这些挫折，NCMI 仍然积极主动，最近回购了价值 940 万美元的股票，并保持稳定的股息支付（每股 0.03 美元）。展望未来，该公司预计 2025 年第三季度收入将增加至 6200 万至 6700 万美元，显示出在持续市场挑战中的潜在稳定和增长。</p>
<ul>
<li>在我们的健康报告中更详细地了解 National CineMedia 的潜力。</li>
<li>通过查看我们的历史报告了解 National CineMedia 的业绩记录。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f205104d-9c46-4a5d-9764-2792c40e1a41/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f205104d-9c46-4a5d-9764-2792c40e1a41/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月 NCMI 盈利和收入增长</p>
<h2>Simulations Plus (SLP)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Simulations Plus, Inc.专注于创建用于药物发现和开发的软件，利用人工智能和机器学习技术，市值约为 2.9969 亿美元。</p>
<p><strong>运营：</strong> SLP 主要通过其软件和服务部门产生收入，软件贡献 4673 万美元，服务贡献 3366 万美元。该公司专注于使用人工智能和机器学习技术开发用于药物发现的先进建模和仿真工具。</p>
<p>Simulations Plus 展现出对创新的强大承诺，特别是通过其人工智能驱动的药物设计（AIDD）计划，最近产生了与免疫反应相关的基因表达的有效化合物。尽管最近遭遇了一些挫折，包括被多个标准普尔指数剔除，但该公司的研发重点依然强劲，支出与其前瞻性收入预期紧密相关。预计盈利将以令人印象深刻的 114.35% 的年增长率增长，并预计在即将到来的财政年度收入增长可达 14%，Simulations Plus 正在高风险的生物技术领域中战略性地定位自己，利用尖端技术潜在地革新治疗开发。</p>
<ul>
<li>在我们的详细健康报告中深入了解 Simulations Plus 的具体情况。</li>
<li>通过查看我们的历史表现报告获取 Simulations Plus 的历史表现见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1af3cc1d-8cff-427a-aa01-39c98e136c6f/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1af3cc1d-8cff-427a-aa01-39c98e136c6f/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 9 月的 SLP 收入和支出细分</p>
<h2>让它发生</h2>
<ul>
<li>在这里浏览 67 只美国高增长科技和人工智能股票的完整清单。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，轻松监控您股票的所有重要指标。</li>
<li>使用 Simply Wall St 应用程序提升您的投资能力，享受覆盖每个大洲的基本市场情报的免费访问。</li>
</ul>
<h2>寻找新的视角？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>为您的投资组合注入显示强劲增长潜力的公司，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

<p>美国股市展现出韧性，尤其是在科技领域，纳斯达克指数上涨了 0.5%。在市场波动中，高增长的科技股受到关注，包括 MiMedx Group、National CineMedia 和 Simulations Plus，这些公司都展现出强大的创新能力和适应性。尽管最近的盈利波动，MiMedx Group 对收入增长持乐观态度，而 National CineMedia 正在应对财务挑战，但预计收入将有所增加。Simulations Plus 专注于基于人工智能的药物发现，预计将实现显著的盈利增长。这些公司体现了当前经济环境中增长的潜力</p>

<p>As major U.S. stock indexes recently closed higher, rebounding from a losing week amid concerns over a potential government shutdown, the tech-heavy Nasdaq showed resilience with a 0.5% gain. In this context of market volatility and economic uncertainty, identifying high-growth tech stocks involves evaluating companies that demonstrate strong innovation capabilities and adaptability to rapidly changing market conditions.</p>
<div class="lb-trans"><p>由于主要的美国股指最近收盘上涨，从因担忧政府可能停摆而导致的亏损周中反弹，科技股占主导的纳斯达克表现出韧性，涨幅为 0.5%。在市场波动和经济不确定性的背景下，识别高增长科技股需要评估那些展现出强大创新能力和适应快速变化市场条件的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美国十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACADIA Pharmaceuticals</td>
<td>10.33%</td>
<td>23.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>ADMA Biologics</td>
<td>20.60%</td>
<td>23.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>25.11%</td>
<td>31.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>65.52%</td>
<td>68.63%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.20%</td>
<td>32.07%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>OS Therapies</td>
<td>56.64%</td>
<td>68.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>28.59%</td>
<td>82.71%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Aldeyra Therapeutics</td>
<td>42.88%</td>
<td>74.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Vanda Pharmaceuticals</td>
<td>22.66%</td>
<td>59.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Gorilla Technology Group</td>
<td>32.75%</td>
<td>122.61%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACADIA 制药</td>
<td>10.33%</td>
<td>23.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>ADMA 生物技术</td>
<td>20.60%</td>
<td>23.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir 技术</td>
<td>25.11%</td>
<td>31.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>65.52%</td>
<td>68.63%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.20%</td>
<td>32.07%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>OS 疗法</td>
<td>56.64%</td>
<td>68.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle 互联网集团</td>
<td>28.59%</td>
<td>82.71%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Aldeyra 治疗学</td>
<td>42.88%</td>
<td>74.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Vanda 制药</td>
<td>22.66%</td>
<td>59.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Gorilla 科技集团</td>
<td>32.75%</td>
<td>122.61%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 67 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国高增长科技和人工智能股票筛选器中的 67 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>在这里，我们重点介绍我们独家的筛选器中的几只最爱。</p>
</div><h2>MiMedx Group (MDXG)</h2>
<div class="lb-trans"><h2>MiMedx 集团 (MDXG)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare, with a market capitalization of approximately $1.03 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> MiMedx 集团公司开发和分销胎盘组织移植物，服务于多个医疗保健领域，市值约为 10.3 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its biotechnology segment, specifically targeting startups, with reported earnings of $363.77 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其生物技术部门产生收入，特别是针对初创企业，报告的收入为 3.6377 亿美元。</p>
</div><p>MiMedx Group, a player in the biotech sector focusing on advanced wound care, is navigating a challenging yet opportunistic landscape. Recently, the company raised its full-year revenue outlook to low double digits, reflecting optimism despite a dip in net income from $17.63 million to $9.62 million in Q2 2025 compared to the previous year. Their strategic alliance with Vaporox hints at aggressive moves into co-promotion and marketing of wound care products, potentially enhancing their market reach and product efficacy. This collaboration alongside an investment in Vaporox could bolster MiMedx's position by integrating innovative therapies like VHT into their offerings, which have shown promising results in clinical studies and real-world applications. Despite facing earnings volatility with a significant drop over the past year (-59.3%), forecasts suggest an earnings growth of 24.6% per annum over the next three years, outpacing both industry and market averages.</p>
<div class="lb-trans"><p>MiMedx 集团是一家专注于先进伤口护理的生物技术公司，正在应对一个充满挑战但充满机会的市场环境。最近，该公司将全年收入预期上调至低双位数，尽管与去年相比，净收入从 1763 万美元下降至 962 万美元。与 Vaporox 的战略联盟暗示了在伤口护理产品的共同推广和市场营销方面的积极举措，可能增强其市场覆盖率和产品有效性。这一合作以及对 Vaporox 的投资可能通过将创新疗法如 VHT 整合到其产品中，提升 MiMedx 的市场地位，这些疗法在临床研究和实际应用中显示出良好的效果。尽管过去一年盈利波动显著下降（-59.3%），但预测显示未来三年年均盈利增长 24.6%，超过行业和市场平均水平。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in MiMedx Group's health report.</li>
<li>Learn about MiMedx Group's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 MiMedx 集团健康报告中的详细发现。</li>
<li>了解 MiMedx 集团的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da86cace-6e02-47ab-b8cb-096c3db7abd9/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/da86cace-6e02-47ab-b8cb-096c3db7abd9/chart/revenue-and-expenses-breakdown"/></p>
<p>MDXG Revenue and Expenses Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 MDXG 收入和支出明细</p>
</div><h2>National CineMedia (NCMI)</h2>
<div class="lb-trans"><h2>National CineMedia (NCMI)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> National CineMedia, Inc. operates a cinema advertising network in North America through its subsidiary, National CineMedia, LLC, with a market capitalization of $434.81 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> National CineMedia, Inc.通过其子公司 National CineMedia, LLC 在北美运营一个影院广告网络，市值为 4.3481 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from advertising, totaling $235.30 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过广告产生收入，总计 2.353 亿美元。</p>
</div><p>Amid a challenging landscape, National CineMedia (NCMI) is navigating through significant financial turbulence, as evidenced by its Q2 2025 results with sales dropping from $54.7 million to $51.8 million year-over-year and a deepened net loss of $10.7 million compared to $8.7 million in the same period last year. Despite these setbacks, NCMI remains proactive, having repurchased shares worth $9.4 million in recent months and maintaining a consistent dividend payout ($0.03 per share). Looking ahead, the company projects an optimistic revenue increase for Q3 2025 to between $62 million and $67 million, signaling potential stabilization and growth amidst ongoing market challenges.</p>
<div class="lb-trans"><p>在一个充满挑战的环境中，National CineMedia (NCMI) 正在经历显著的财务动荡，其 2025 年第二季度的结果显示，销售额同比从 5470 万美元下降至 5180 万美元，净亏损从去年同期的 870 万美元加深至 1070 万美元。尽管面临这些挫折，NCMI 仍然积极主动，最近回购了价值 940 万美元的股票，并保持稳定的股息支付（每股 0.03 美元）。展望未来，该公司预计 2025 年第三季度收入将增加至 6200 万至 6700 万美元，显示出在持续市场挑战中的潜在稳定和增长。</p>
</div><ul>
<li>Take a closer look at National CineMedia's potential here in our health report.</li>
<li>Understand National CineMedia's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的健康报告中更详细地了解 National CineMedia 的潜力。</li>
<li>通过查看我们的历史报告了解 National CineMedia 的业绩记录。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f205104d-9c46-4a5d-9764-2792c40e1a41/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/f205104d-9c46-4a5d-9764-2792c40e1a41/chart/earnings-and-revenue-growth"/></p>
<p>NCMI Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 NCMI 盈利和收入增长</p>
</div><h2>Simulations Plus (SLP)</h2>
<div class="lb-trans"><h2>Simulations Plus (SLP)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Simulations Plus, Inc. specializes in creating software for drug discovery and development that leverages artificial intelligence and machine learning technologies, with a market cap of approximately $299.69 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Simulations Plus, Inc.专注于创建用于药物发现和开发的软件，利用人工智能和机器学习技术，市值约为 2.9969 亿美元。</p>
</div><p><strong>Operations:</strong> SLP generates revenue primarily through its software and services segments, with software contributing $46.73 million and services adding $33.66 million. The company focuses on developing advanced modeling and simulation tools for drug discovery using AI and machine learning technologies.</p>
<div class="lb-trans"><p><strong>运营：</strong> SLP 主要通过其软件和服务部门产生收入，软件贡献 4673 万美元，服务贡献 3366 万美元。该公司专注于使用人工智能和机器学习技术开发用于药物发现的先进建模和仿真工具。</p>
</div><p>Simulations Plus has demonstrated a robust commitment to innovation, particularly through its artificial intelligence-driven drug design (AIDD) initiatives, which recently yielded potent compounds for gene expression related to immune responses. Despite recent setbacks including being dropped from several S&amp;P indices, the company's R&amp;D focus remains strong with expenditures that align closely with its forward-looking revenue projections. With earnings expected to grow by an impressive 114.35% annually and a forecasted revenue increase of up to 14% in the coming fiscal year, Simulations Plus is strategically positioning itself in the high-stakes biotech sector, leveraging cutting-edge technology to potentially revolutionize therapeutic development.</p>
<div class="lb-trans"><p>Simulations Plus 展现出对创新的强大承诺，特别是通过其人工智能驱动的药物设计（AIDD）计划，最近产生了与免疫反应相关的基因表达的有效化合物。尽管最近遭遇了一些挫折，包括被多个标准普尔指数剔除，但该公司的研发重点依然强劲，支出与其前瞻性收入预期紧密相关。预计盈利将以令人印象深刻的 114.35% 的年增长率增长，并预计在即将到来的财政年度收入增长可达 14%，Simulations Plus 正在高风险的生物技术领域中战略性地定位自己，利用尖端技术潜在地革新治疗开发。</p>
</div><ul>
<li>Dive into the specifics of Simulations Plus here with our thorough health report.</li>
<li>Gain insights into Simulations Plus' historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的详细健康报告中深入了解 Simulations Plus 的具体情况。</li>
<li>通过查看我们的历史表现报告获取 Simulations Plus 的历史表现见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1af3cc1d-8cff-427a-aa01-39c98e136c6f/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/1af3cc1d-8cff-427a-aa01-39c98e136c6f/chart/revenue-and-expenses-breakdown"/></p>
<p>SLP Revenue and Expenses Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SLP 收入和支出细分</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>让它发生</h2>
</div><ul>
<li>Navigate through the entire inventory of 67 US High Growth Tech and AI Stocks here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里浏览 67 只美国高增长科技和人工智能股票的完整清单。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，轻松监控您股票的所有重要指标。</li>
<li>使用 Simply Wall St 应用程序提升您的投资能力，享受覆盖每个大洲的基本市场情报的免费访问。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>寻找新的视角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>为您的投资组合注入显示强劲增长潜力的公司，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>

探讨美国市场中的三只高增长科技股票